BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36018850)

  • 1. S146L in MYC is a context-dependent activating substitution in cancer development.
    Hinds JW; Feris EJ; Wilkins OM; Deary LT; Wang X; Cole MD
    PLoS One; 2022; 17(8):e0272771. PubMed ID: 36018850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cellular Protein Complex Associated with a Transforming Region of E1A Contains c-MYC.
    Vijayalingam S; Subramanian T; Zhao LJ; Chinnadurai G
    J Virol; 2016 Jan; 90(2):1070-9. PubMed ID: 26559831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
    D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
    Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation of a structurally-stable conformation by the intrinsically disordered MYC:TRRAP complex.
    Feris EJ; Hinds JW; Cole MD
    PLoS One; 2019; 14(12):e0225784. PubMed ID: 31790487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC interacts with the human STAGA coactivator complex via multivalent contacts with the GCN5 and TRRAP subunits.
    Zhang N; Ichikawa W; Faiola F; Lo SY; Liu X; Martinez E
    Biochim Biophys Acta; 2014 May; 1839(5):395-405. PubMed ID: 24705139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation.
    Liu X; Tesfai J; Evrard YA; Dent SY; Martinez E
    J Biol Chem; 2003 May; 278(22):20405-12. PubMed ID: 12660246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.
    Thng DKH; Toh TB; Chow EK
    Trends Pharmacol Sci; 2021 Mar; 42(3):166-182. PubMed ID: 33422376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins.
    Nikiforov MA; Chandriani S; Park J; Kotenko I; Matheos D; Johnsson A; McMahon SB; Cole MD
    Mol Cell Biol; 2002 Jul; 22(14):5054-63. PubMed ID: 12077335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
    Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
    Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E2F transcriptional activation requires TRRAP and GCN5 cofactors.
    Lang SE; McMahon SB; Cole MD; Hearing P
    J Biol Chem; 2001 Aug; 276(35):32627-34. PubMed ID: 11418595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attacking c-Myc: targeted and combined therapies for cancer.
    Huang H; Weng H; Zhou H; Qu L
    Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.
    Vízkeleti L; Spisák S
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HAUSP regulates c-MYC expression via de-ubiquitination of TRRAP.
    Bhattacharya S; Ghosh MK
    Cell Oncol (Dordr); 2015 Aug; 38(4):265-77. PubMed ID: 25925205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins.
    McMahon SB; Van Buskirk HA; Dugan KA; Copeland TD; Cole MD
    Cell; 1998 Aug; 94(3):363-74. PubMed ID: 9708738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal location targets different MYC family gene members for oncogenic translocations.
    Gostissa M; Ranganath S; Bianco JM; Alt FW
    Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2265-70. PubMed ID: 19174520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC in oncogenesis and as a target for cancer therapies.
    Albihn A; Johnsen JI; Henriksson MA
    Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC Analysis in Cancer and Evolution.
    Hartl M; Bister K
    Methods Mol Biol; 2021; 2318():87-117. PubMed ID: 34019288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A druggable conformational switch in the c-MYC transactivation domain.
    Lama D; Vosselman T; Sahin C; Liaño-Pons J; Cerrato CP; Nilsson L; Teilum K; Lane DP; Landreh M; Arsenian Henriksson M
    Nat Commun; 2024 Feb; 15(1):1865. PubMed ID: 38424045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.
    Stefan E; Bister K
    Curr Top Microbiol Immunol; 2017; 407():117-151. PubMed ID: 28466200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the Ras/mitogen-activated protein kinase pathway.
    Kapeli K; Hurlin PJ
    J Biol Chem; 2011 Nov; 286(44):38498-38508. PubMed ID: 21908617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.